Skip to main content

Understanding and exploiting epigenetic regulation in CAR T cell therapy

Project description

Delving into the epigenetics of CAR T cell therapy

Chimeric antigen receptor T cells (CAR Ts) are a new approach for boosting a patient’s immune system to fight cancer. CAR Ts are patient cells engineered to detect specific antigens on cancer cells and destroy them. The scope of the EU-funded EPI-CART project is to increase our understanding of CAR Ts from an epigenetic perspective, something that hasn’t been investigated before. Researchers will undertake epigenetic and transcriptomic profiling of these cells after transplantation. Linking this information with immune regulation will uncover epigenetic drivers of CAR T cell response and help optimise this immunotherapy for solid tumours.

Call for proposal

ERC-2020-COG
See other projects for this call

Host institution

CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
Address
Lazarettgasse 14 Akh Bt 25.3
1090 Wien
Austria
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 1 999 913

Beneficiaries (1)

CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
Austria
EU contribution
€ 1 999 913
Address
Lazarettgasse 14 Akh Bt 25.3
1090 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)